GlassScriptPhysician profile
Timothy G Davis
NPI 1619377199
$11,959.49
in general payments reported to CMS, 2019-2025
40 companies · $1,504 in 2025
The $1,504 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,380 · 2022: $2,726 · 2023: $2,520 · 2024: $829 · 2025: $1,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,817 · Education: $36.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,816.86 |
| Education | $36.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,979.63 | 2021-2025 | |
| Novo Nordisk INC | $1,274.23 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $872.08 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $763.49 | 2021-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $724.23 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $588.99 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $583.51 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Biohaven Pharmaceuticals, INC. | $570.97 | 2021 | |
| Esperion Therapeutics, INC. | $425.50 | 2021-2023 | Nexletol |
| Abbott Laboratories | $364.43 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $327.61 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $229.64 | 2022 | |
| Pfizer INC. | $224.49 | 2021-2025 | |
| Dexcom, INC. | $198.77 | 2022-2024 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $178.92 | 2021-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.